This partnership will help facilitate a dual antigen-carrying intranasal vaccine without the requirement for intramuscular injection. This delivery method will provide cost-effective vaccines for some of the world’s hardest-to-reach communities.
“We are thrilled to enter into this collaboration agreement with FARVET SAC, who have extensive experience in the fields of vaccine delivery and manufacturing. By combining our resources, we will ensure the highest standard of quality in our work to make vaccines more available, both logistically and financially. We look forward to working together with these industry experts towards our goal of improving global health outcomes,” says Jon Chadwick, CEO of ViraCorp.
FARVET SAC is a Peruvian pharmaceutical firm with over 30 years of experience in researching and developing veterinary vaccines from their laboratories in Chincha, Peru. With extensive experience in researching coronaviruses and executing vaccine pipelines, the company is uniquely equipped to tackle the COVID-19 pandemic. Manolo Fernández, CEO of the company, has successfully researched and delivered a number of vaccines throughout his distinguished career.
“FARVET is always looking to innovate and develop new technologies, which will help to reduce the threats posed by respiratory diseases. We are excited to collaborate with ViraVac, Incepta, and the Lancaster University to bring this intranasal vaccine through clinical trials and support the efficient control of the COVID-19 pandemic,” he said.
“For our company, conducting clinical trials in Peru fills us with a great sense of pride, and we are eager to begin working to deliver this game-changing technology in the near future.”
The parties are partnering to bring a no-needle alternative vaccine to market, facilitating immunisation efforts at low cost for remote and impoverished communities, as well as providing an alternative for patients suffering from needle-phobia. The intranasal vaccine induces a special type of antibodies in the respiratory tract as the first line of defence against the virus. This characteristic is not found in currently available needle-delivery vaccines.
The technology behind this vaccine is state-of-the-art, showing exceptional efficacy against all known strains of COVID-19 in pre-clinical testing.
ViraCorp Chief Scientific Officer and renowned molecular virologist Dr Muhammad Munir, of Lancaster University, said: “I am thrilled that ViraVac is partnering with FARVET to deliver a vaccine which I believe will have significant impact in global communities.